NeuroSense Shares Are Trading Higher After the Company Announced an Alzheimer's Drug Development Collaboration With Genetika+.

NeuroSense Shares Are Trading Higher After the Company Announced an Alzheimer's Drug Development Collaboration With Genetika+.

BenzingaApr 22 20:33

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning With Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases announced...

PR NewswireApr 22 20:30

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces...

PR NewswireApr 18 20:30

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces...

PR NewswireApr 12 20:30

Reported Earlier, NeuroSense Therapeutics Prices $4.5M Registered Direct Offering Of 2.98M Shares And Concurrent Private Placement

NeuroSense Therapeutics Ltd, a company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a single health-care

BenzingaApr 11 14:23

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

CAMBRIDGE, Mass., April 10, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company developing novel treatments for severe neurodegenerative diseas

PR NewswireApr 11 07:16